SCHEMBL18606919

SCHEMBL18606919

Nc1cc(-c2cnc3ccccn23)ccn1

nearest known ligand 0.58

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MIF P14174 1/20 0.58
FLT3 P36888 3/20 0.55
PKM P14618 2/20 0.54
PIK3CA P42336 1/20 0.49
DYRK1A Q13627 1/20 0.48
IKBKE Q14164 1/20 0.47
TBK1 Q9UHD2 1/20 0.47
KDR P35968 3/20 0.47
PRMT5 O14744 1/20 0.46
WDR77 Q9BQA1 1/20 0.46
RIPK2 O43353 1/20 0.46
ADORA3 P0DMS8 1/20 0.42
IRAK4 Q9NWZ3 3/20 0.42
KIT P10721 1/20 0.42
CDK2 P24941 1/20 0.42
MAPK8 P45983 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL73445 0.80 MIF (0.60) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL15757581 0.79 FLT3 (0.68) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL22394780 0.79 BACE1 (0.67) PKMPIK3CADYRK1ARIPK2
SCHEMBL25261576 0.78 FLT3 (0.71) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL72955 0.77 CDK2 (0.50) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL2650330 0.77 FLT3 (0.74) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL22919154 0.76 PKM (0.57) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL34464684 0.76 PKM (0.57) MIFFLT3PKMPIK3CADYRK1A
SCHEMBL29868755 0.76 PKM (0.54) MIFFLT3PKMDYRK1AADORA3
SCHEMBL25416552 0.76 KDM4E (0.53) DYRK1AADORA3CDK2MAPK8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3345906-B1 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO LTD (CN) 2022-05-25 EP disclosed
EP-3345906-B1 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO LTD (CN) 2022-05-25 EP disclosed
US-10377747-B2 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2019-08-13 US disclosed
US-10377747-B2 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2019-08-13 US disclosed
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2018-07-26 US disclosed
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2018-07-26 US disclosed
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF WUXI SHUANGLIANG BIOTECHNOLOGY CO., LTD. (CN) 2018-07-26 US disclosed
EP-3345906-A1 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF Wuxi Shuangliang Biotechnology Co., Ltd. (CN) 2018-07-11 EP disclosed
CN-106132957-B 2-arylamino pyridine, pyrimidine or triazine derivative and preparation method and application thereof 无锡双良生物科技有限公司 2018-06-12 CN disclosed
WO-2017035753-A1 2-ARYLAMINO PYRIDINE, PYRIDINE OR TRIAZINE DERIVATIVE, PREPARATION METHOD AND USE THEREOF 无锡双良生物科技有限公司 2017-03-09 WO disclosed
CN-106132957-A 2-arylamino pyridine, pyrimidine or triazine derivative and preparation method and application thereof 无锡双良生物科技有限公司 2016-11-16 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180208585-A1 2-ARYLAMINO PYRIDINE, PYRIMIDINE OR TRIAZINE DERIVATIVES, PREPARATION METHOD AND USE THEREOF ERBB2, EGFR, ERBB3 MIF 4594/4885FLT3 6/4885PKM 2547/4885
US-10377747-B2 2-arylamino pyridine, pyrimidine or triazine derivatives, preparation method and use thereof ERBB2, EGFR, ERBB3 MIF 4616/4885FLT3 6/4885PKM 2021/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.